[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355406-105":59,"doc-detail-355406-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","a-double-negative-prostate-cancer-subtype-is-vulnerable-to-swisnf-targeting-degrader-molecules","A Double-Negative Prostate Cancer Subtype Is Vulnerable to SWI/SNF-Targeting Degrader Molecules","","Proteolysis-targeting chimera (PROTAC) therapies that degrade SWI/SNF ATPases disrupt androgen receptor (AR) signaling in AR-dependent castration-resistant prostate cancer, but their broader potential remained unclear. The study tests SWI-/SNF-targeting PROTACs in AR-negative CRPC, showing reduced viability in both CRPC-AR and WNT signaling–dependent AR-negative CRPC. SMARCA4 depletion blocks TCF7L2 activity and limits MAPK-driven proliferation, providing a mechanistic basis for targeting DNA binding and/or MAPK signaling in the CRPC-WNT subgroup.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-double-negative-prostate-cancer-subtype-is-vulnerable-to-swisnf-targeting-degrader-molecules/355406/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-double-negative-prostate-cancer-subtype-is-vulnerable-to-swisnf-targeting-degrader-molecules/355406.png","ImageObject",300,407,{"name":92,"@type":93},"\tCallum ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What problem does the study address in prostate cancer treatment?","Question",{"text":113,"@type":114},"It investigates how lineage plasticity leads to aggressive cancers that become less responsive to targeted therapies, focusing on transitions to AR-negative castration-resistant prostate cancer.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How do SWI/SNF-targeting PROTAC treatments affect AR-negative CRPC models?",{"text":118,"@type":114},"SWI-/SNF-targeting PROTACs reduce viability in AR-negative CRPC, including WNT signaling–dependent AR-negative CRPC (CRPC-WNT).",{"name":120,"@type":111,"acceptedAnswer":121},"Which molecular regulators are implicated in the CRPC-WNT vulnerability described?",{"text":122,"@type":114},"SMARCA4 depletion interferes with the transcriptional regulator TCF7L2, and TCF7L2 supports proliferation through MAPK signaling in this subtype.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},355406,1790186619,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":36,"preview_page_count":19,"preview_urls":146},137451211410,"https://ap-avatar.wpscdn.com/avatar/2000bb0a9246f588df?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786362646172706240","A Double-Negative Prostate Cancer Subtype Is Vulnerable to SWI/SNF-Targeting Degrader Molecules  \nPhillip Thienger1, Irene Paassen1, Xiaosai Yao2,3, Philip D. Rubin1, Marika Lehner1, Nicholas Lillis4, Andrej Benjak1, Sagar R. Shah5, Alden King-Yung Leung5, Simone de Brot6, Alina Naveed1, Bence Daniel7, Minyi Shi7, Julien Tremblay3, Joanna Triscott1, Giada Andrea Cassanmagnago8,9,10, Marco Bolis8,9,10, Lia Mela1, Himisha Beltran11, Yu Chen12,13,14, Salvatore Piscuoglio15, Haiyuan Yu5, Charlotte K.Y. Ng16,17, David A. Quigley4,18,19, Robert L. Yauch2, and Mark A. Rubin1,17,20  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Proteolysis-targeting chimera (PROTAC) therapies degrading SWI/SNF ATPases interfere with androgen receptor (AR) signaling in AR-dependent castration-resistant prostate cancer (CRPC-AR). To explore the utility of SWI/SNF therapy beyond AR-sensitive CRPC, we investigated SWI-/SNF-targeting agents in AR-negative CRPC. SWI-/SNF-targeting PROTAC treatment of cell lines and organoid models reduced the viability of not only CRPC-AR but also WNT signaling–dependent AR-negative CRPC (CRPCWNT). The CRPC-WNT subgroup represents 11% of around 400,000 cases of CRPC worldwide that die yearly. SWI/SNF ATPase SMARCA4 depletion interfered with the master transcriptional regulator TCF7L2 in CRPC-WNT. Functionally, TCF7L2 maintained proliferation via the MAPK signaling axis in this subtype of CRPC. Together, these data provide a mechanistic rationale for interventions that perturb DNA binding of the proproliferative transcription factor TCF7L2 and/or direct MAPK signaling inhibition in the CRPC-WNT subclass of advanced prostate cancer.\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Significance: SWI/SNF-targeting agents interfere with a lineagedefining molecular axis in the WNT signaling–dependent, androgen receptor-negative subtype of prostate cancer, which accounts for around 10% of castration-resistant tumors.\u003Cbr>\u003Cbr>SMARCA2/4\u003Cbr>SMARCA2/4 active\u003Cbr>TCF-/LEF-binding domain (”open”)\u003Cbr>Complex assembly\u003Cbr>Proproliferative transcripts e.g. , MAPK activators\u003Cbr>TCF/LEF binding domain (”open”)\u003Cbr>Created in BioRender. Thienger, P. (2025) [https://BioRender.com/idfhs6i](https://BioRender.com/idfhs6i) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nTreatment-induced shifts in cancer cell identity, known as lineage plasticity (LP), lead to the emergence of tumors that may have little-tono resemblance to the treatment-nave tumors. The increased and earlier use of potent targeted cancer therapies is responsible for the emergence of aggressive, “plastic,” and untreatable cancers. In prostate cancer, LP can manifest when androgen receptor (AR)–driven adenocarcinoma [AR-dependent castration-resistant prostate cancer (CRPC-AR)] differentiates into AR-negative CRPC, which lacks both canonical AR signaling and neuroendocrine (NE) differentiation markers [doublenegative","cbCainkjVit4FSA1","https://ap.wps.com/l/cbCainkjVit4FSA1","pdf",18633028,16,"English","# Introduction\n## Lineage plasticity and prostate cancer subtypes\n## Role of SWI/SNF chromatin remodeling\n## Dysregulation of SMARCA2/SMARCA4 in CRPC","[{\"question\":\"What problem does the study address in prostate cancer treatment?\",\"answer\":\"It investigates how lineage plasticity leads to aggressive cancers that become less responsive to targeted therapies, focusing on transitions to AR-negative castration-resistant prostate cancer.\"},{\"question\":\"How do SWI/SNF-targeting PROTAC treatments affect AR-negative CRPC models?\",\"answer\":\"SWI-/SNF-targeting PROTACs reduce viability in AR-negative CRPC, including WNT signaling–dependent AR-negative CRPC (CRPC-WNT).\"},{\"question\":\"Which molecular regulators are implicated in the CRPC-WNT vulnerability described?\",\"answer\":\"SMARCA4 depletion interferes with the transcriptional regulator TCF7L2, and TCF7L2 supports proliferation through MAPK signaling in this subtype.\"}]","A Double-Negative Prostate Cancer Subtype Is Vulnerable to SWI/SNF-Targeting Degrader Molecules | PDF",1790118629,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/14b65a5ff5625b19456a71e6eb8d072f.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a0dfeba89cd107a6b71ca1eb0a811ce0.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/851294d653da4d53cc3e9629bd427953.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/04b4bf597265ac3594af9a5cd6d1be2f.webp",980,1311]